Hormone Therapy

  • Alexander PrattEmail author


Hormone therapy including hormone replacement therapy (HRT), oral contraceptive pills (OCPs), and testosterone is commonly used. OCPs and HRT are associated with an increased risk of venous thromboembolism (VTE). Perioperative consultants may be asked to provide recommendations for the risks and/or management of these medications perioperatively. This chapter provides an overview of risks of use of hormone therapy around the time of surgery and suggestions for management.


Hormone replacement therapy Estrogen Testosterone Venous thromboembolism Coronary artery disease 


  1. 1.
    Lidegaard O, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;343:d6423.CrossRefGoogle Scholar
  2. 2.
    Canonico M, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336:1227. Open image in new windowCrossRefGoogle Scholar
  3. 3.
    Canonico M, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: sytematic review an meta-analysis. BMJ Online First. 2008;336:1227.CrossRefGoogle Scholar
  4. 4.
    Cushman M, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573. Open image in new windowCrossRefGoogle Scholar
  5. 5.
    Anderson GL, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Womans health initiative randomized controlled trial. JAMA. 2004;291(14):1701.CrossRefGoogle Scholar
  6. 6.
    Wierckx K, et al. Long-term evaluation of cross-sex hormone treatment in transexual persons. J Sex Med. 2012;9:2641–51.CrossRefGoogle Scholar
  7. 7.
    Maged Y, et al. Association of testosterone replacement therapy and the incidence of a composite of postoperative in-hospital mortality and cardiovascular events in men undergoing noncardiac surgery. Anesthesiology. 2017;127:457–65. Open image in new windowCrossRefGoogle Scholar
  8. 8.
    de Bastos M, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;(3):CD010813.Google Scholar
  9. 9.
    Vandenbroucke JP, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344(8935):1453.CrossRefGoogle Scholar
  10. 10.
    van Vlijmen EF, et al. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med. 2007;167(3):282.CrossRefGoogle Scholar
  11. 11.
    Hussain T, Kneeshaw PJ. Stopping tamoxifen peri-operatively for VTE risk reduction: a proposed management algorithm. Int J Surg. 2012;10(6):313–6. Epub 2012 May 16.CrossRefGoogle Scholar
  12. 12.
    Ellis AJ, Hendrick VM, Williams R, Komm BS. Selective estrogen receptor modulators in clinical practice: a safety overview. Expert Opin Drug Saf. 2015;14(6):921–34.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Medicine, Division of General Internal MedicineUniversity of WashingtonSeattleUSA

Personalised recommendations